[Crizotinib treatment for a lung adenocarcinoma patient with anaplastic lymphoma kinase gene rearrangement and disseminated intravascular coagulation]

Zhonghua Zhong Liu Za Zhi. 2021 Nov 23;43(11):1195-1196. doi: 10.3760/cma.j.cn112152-20200611-00549.

[Article in Chinese]

Authors

S Wang¹, S M Li¹, X Wu¹, H Zhu¹, Q M Wang¹

Affiliation

¹ Department of Respiratory Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.

PMID: 34794223
DOI: 10.3760/cma.j.cn112152-20200611-00549

No abstract available

Keywords: Anaplastic lymphoma kinase; Crizotinib; Disseminated intravascular coagulation; Lung adenocarcinoma.

MeSH terms

Adenocarcinoma of Lung* / drug therapy
Adenocarcinoma of Lung* / genetics
Anaplastic Lymphoma Kinase / genetics
Crizotinib
Disseminated Intravascular Coagulation* / drug therapy
Gene Rearrangement
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Protein Kinase Inhibitors

Substances

Protein Kinase Inhibitors
Crizotinib
Anaplastic Lymphoma Kinase